Mizuho Cuts Upstream Bio (NASDAQ:UPB) Price Target to $50.00

Upstream Bio (NASDAQ:UPB) had its target price lowered by Mizuho from $51.00 to $50.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price target indicates a potential upside of 434.19% from the company’s current price.

UPB has been the topic of several other reports. Weiss Ratings downgraded Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Wall Street Zen cut Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $38.75.

Upstream Bio Stock Up 4.6%

Shares of NASDAQ:UPB opened at $9.36 on Thursday. The stock has a market capitalization of $509.37 million, a PE ratio of -3.51 and a beta of 1.28. The firm’s 50 day moving average price is $9.20 and its 200-day moving average price is $19.36. Upstream Bio has a twelve month low of $7.25 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.04. The business had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.62 million. Upstream Bio had a negative net margin of 5,026.03% and a negative return on equity of 36.48%. Analysts expect that Upstream Bio will post -3.06 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Integral Health Asset Management LLC purchased a new position in shares of Upstream Bio in the third quarter valued at $10,816,000. Jennison Associates LLC purchased a new stake in Upstream Bio during the fourth quarter valued at $7,842,000. Pictet Asset Management Holding SA purchased a new stake in Upstream Bio during the fourth quarter valued at $20,991,000. UBS Group AG lifted its position in Upstream Bio by 563.4% during the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after purchasing an additional 1,533,972 shares during the last quarter. Finally, Torren Management LLC bought a new position in Upstream Bio during the fourth quarter valued at $30,000.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.